Heranba Industries Limited · NSE:HERANBA
Heranba Industries — Q1 FY2025 Earnings Presentation
30 slides from Heranba Industries's earnings presentation, Aug 12, 2024
Slide 1: Exchange filing letter for Q1 FY2025 investor presentation
August 12, 2024 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Plot no. C/l, G Block, Mumbai- 400001, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 051. Scrip Code: 543266 Symbol: HERANBA Dear Sir/Madam, Sub: Investor Presen
Slide 2: Investor Presentation Q1FY25
Investor Presentation Q1FY25 || August 2024 BSE: 543266 | NSE: HERANBA | ISIN: INE694N01015 www.heranba.co.in
Slide 3: Safe Harbor
Safe This presentation and the accompanying slides (the “Presentation”), which have been prepared by Heranba Industries Harbor Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any se
Slide 4: Contents
Contents Company Overview 01 SLIDE 04 Management Team 02 SLIDE 11 Quarterly Performance 03 SLIDE 13 Financial Performance 04 SLIDE 18 Strategy for Growth 05 SLIDE 25
Slide 5: Company Overview
Section: 01 Company Overview Heranba at glance Our journey Value chain SLIDE 05 SLIDE 06 SLIDE 07 Intermediaries Technicals Formulations SLIDE 08 SLIDE 09 SLIDE 10
Slide 6: Heranba at a Glance
Heranba at a Glance 60+ 4 65+ 1050+ Revenue from Institutional Manufacturing Countries Employees customers** Facilities Presence (as of FY24) (as of FY24) 8500+ 35% ~15% Dealers Revenue from Revenue from 7.8% Exports as % of sales Top 10 customers ROE# across India (as of FY24) (as of FY24) (as of F
Slide 7: Our Journey
Our Journey FORMULATIONS ISO CERTIFICATE EXPORTS Forward integrated into the Receipt of ISO 9001:2015 Exported Technicals and manufacturing of Formulations developed certification in respect of production Formulations to more ACQUISITION from Company’s synthetic pyrethroids & dispatch of agro Formul
Slide 8: Value Chain
Value Chain Manufacturing Process The process of manufacturing HIL manufactures a wide range of products, and each product has its can be classified broadly into own unique manufacturing process three stages Value Chain The Company specializes in the manufacturing processes that mainly include
Slide 9: Intermediaries
Intermediaries Cypermethric Acid Chloride (CMAC) End-use High CIS CMA High Trans CMA Intermediates manufactured are for Company’s own captive consumption for manufacturing various Technicals and Formulations Metaphenoxy High Trans CMAC Bromobenzenes Benzaldehyde (MPBD)
Slide 10: Technicals
Technicals Herbicides Glyphosate Metribuzin Insecticides Clodinofop Cypermethrin Deltamethrin Alpha Cypermethrin Acephate Lambda Cyhalothrin Permethrin Technicals Profenophos Temephos Theta Cypermethrin Thiamethoxam Imidacloprid Fungicides Tricyclazole Hexaconazole
Slide 11: Formulations
Formulations Revenue from Technical and Formulations Herbicides (₹ in Crore) Glory Glory 71 Chakde Shera Insecticides Heraquat Pendant Jayam Zinta Atria Progress Plus Param Cypraplus Dyken 967 Mantra Formulations 857 763 728 Astron 648 638 636 554 Signor 468 362 Pro
Slide 12: Management
An ISO 9001:2015 Company (@) HERANBA INDUSTRIES LIMITED Section: 02 Management
Slide 13: Experienced Promoters with Domain Knowledge
Experienced Promoters with Domain Knowledge Promoters having a cumulative experience of more than six decades Mr. Sadashiv K. Shetty Mr. Raghuram K. Shetty Chairman and Executive Director Managing Director Holds a bachelor’s (physics and chemistry) and master’s (chemistry) Holds a bachelor’s deg
Slide 14: Quarterly Performance
Section: 03 Quarterly Performance Management Quarterly P&L Summary Commentary Performance SLIDE 16 & 17 SLIDE 14 SLIDE 15
Slide 15: FY25 Management Commentary
FY25 Management Commentary Mr. Raghuram K. Shetty, Managing Director of Heranba Industries Limited, commented, “I am pleased to report that we have maintained our growth momentum in the first quarter of FY25 by reporting a strong set of numbers. We saw an increase of 6% in our revenues and 17 Crores
Slide 16: Quarterly Performance (Standalone)
Quarterly Performance (Standalone) Net Revenue from EBITDA(incl. Other Rev) PAT and PAT Margin Business Mix Operations and EBITDA Margin ( ₹ I N CR O R E & % ) (IN %) ( ₹ I N CR O R E ) ( I N ₹ CR O R E & % ) 310 20.00% 12.00% 12% 300 18.00% 18% 20% 10.00% 16.00% 290 9% 18.86% 14.00% 8.00% 40% 11.30
Slide 17: Profit & Loss Summary (Standalone)
Profit & Loss Summary (Standalone) (Quarterly) Figures in Crores, except EPS and Margins PARTICULARS Q1FY24 Q4FY24 Q1FY25 Revenue from Operations 282.40 261.29 304.35 Other Income 8.06 10.43 9.19 Total Revenue 290.30 271.72 313.54 Total Expenses 288.27 253.41 266.78 Profit Before Tax 2.03 18.31 46.7
Slide 18: Profit & Loss Summary (Consolidated)
Profit & Loss Summary (Consolidated) (Quarterly) Figures in Crores, except EPS and Margins PARTICULARS Q1FY24 Q4FY24 Q1FY25 Revenue from Operations 275.21 257.91 296.25 Other Income 5.79 4.51 1.14 Total Revenue 281.00 262.42 297.39 Total Expenses 287.17 258.74 273.76 Profit Before Tax -6.17 3.68 23.
Slide 19: Financial Performance
Section: 04 Financial Performance Key Ratios Financial Summary SLIDE 19 SLIDE 21
Slide 20: Key Financial Metrics (Standalone)
Key Financial Metrics (Standalone) Net Revenue EBITDA(incl. Other Rev) PAT and Net Debt/(Cash) from Operations and EBITDA Margin PAT Margin and Equity ( ₹ I N CR O R E ) ( I N ₹ CR O R E & % ) ( ₹ I N CR O R E & % ) ( ₹ I N CR O R E ) 18.63% 18.99% 13.04% 12.66% 10.26% 15.07% 117.07 8.31% 13.05% 5.2
Slide 21: Standalone Business Mix
Standalone Business Mix Diversified customers base across geographies helps to mitigate risks and benefit from expected growth in agrochemical market Revenue from Operations Revenue from Domestic / Exports (IN%) (% OF SALES) Export Revenue Split: Technical and Formulations Export 22% 32% 28% 35% 36%
Slide 22: Profit & Loss Summary (Standalone)
Profit & Loss Summary (Standalone) (₹ IN CRORE) PARTICULARS FY20 FY21 FY22 FY23 FY24 Revenue from Operations 951.37 1218.65 1450.37 1324.38 1274.75 Other Income 16.53 7.03 19.35 13.58 30.39 Total Revenue 967.91 1225.68 1469.72 1337.96 1305.14 Total Expenses 839.06 1017.39 1214.47 1193.82 1214.75 Pro
Slide 23: Standalone Balance Sheet (1/2)
Standalone Balance Sheet (1/2) (₹ IN CRORE) PARTICULARS FY20 FY21 FY22 FY23 FY24 Non-Current Assets Property, plant and equipment 95.44 133.44 193.42 185.99 239.66 Capital work-in-progress 37.77 9.70 14.23 42.04 11.32 Financial Assets: (i) Investments 3.73 10.10 2.13 0.92 1.83 (ii) Loans 53.19 299.6
Slide 24: Standalone Balance Sheet (2/2)
Standalone Balance Sheet (2/2) (₹ IN CRORE) PARTICULARS FY20 FY21 FY22 FY23 FY24 Equity and liabilities Equity Equity share capital 39.06 40.01 40.01 40.01 40.01 Other equity 281.79 488.12 674.44 776.10 837.45 Total Equity 320.85 528.13 714.45 816.11 877.46 Liabilities Non-Current Liabilities Financ
Slide 25: Standalone Cashflow Statement
Standalone Cashflow Statement (₹ IN CRORE) PARTICULARS FY20 FY21 FY22 FY23 FY24 Cash Flow from Operations 54.21 60.4 98.11 122.50 149.41 Cash Flow from Investing Activities -52.04 -40.71 -81.72 -100.06 -266.71 Cash Flow from financing Activities -19.94 61.9 -6.27 -18.08 29.93 Net increase/ (decrease
Slide 26: Consolidated Cashflow Statement
Consolidated Cashflow Statement (₹ IN CRORE) PARTICULARS FY24 Cash Flow from Operations 107.20 Cash Flow from Investing Activities (240.91) Cash Flow from financing Activities 62.02 Net increase/ (decrease) in cash and cash equivalents (71.69) Cash and cash equivalents at beginning of the year 100.0
Slide 27: Strategy for growth
Section: 05 Strategy for growth Competetive Strengths Business Strategy SLIDE 26 SLIDE 27
Slide 28: Competitive Strengths
Competitive Strengths Experienced Promoters and Management Team Wide Distribution Wide range of products Network across value chain Integrated Diversified Manufacturing Units Customer Base Exports to more Product Registration than 60 countries enabling global outreach
Slide 29: Business Strategy
Business Strategy Well positioned to exploit opportunities offered by growth in Agrochemicals Entering Highly Strengthening of Enhancing Enhancing Branded Regulated USA and R&D Facility Production Formulation Formulations and Europe markets Capabilities & Technicals in Public Health International Ma
Slide 30: Thank You
Corporate Office Heranba Industries Ltd. 101/102, Kanchanganga, Factory Lane, Borivali (W), Mumbai – 400 092, India Tel : 91-22-2898 7912/14, 91-22-2898 2133/44, 91-22-2898 4439, 91-22-5070 5050 Thank You Email : compliance@heranba.com